List view / Grid view
1 June 2017 | By Niamh Marriott, Junior Editor
The EC has granted marketing authorisation for Ionis Pharmaceuticals’ Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA)...
18 July 2016 | By Victoria White, Digital Content Producer
At an estimated $4billion a year, the reference product, Humira, is among the European Union's largest single drug expenditures...
5 July 2016 | By Victoria White, Digital Content Producer
The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS...
9 June 2016 | By Victoria White, Digital Content Producer
Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR...
7 June 2016 | By Victoria White, Digital Content Producer
The primary endpoint primary endpoint was a multicomponent measure evaluating improvement of physical function, cognitive function, and disability...
2 June 2016 | By Victoria White, Digital Content Producer
PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
3 May 2016 | By Victoria White, Digital Content Producer
The new company, to be named at a later date, will focus on the discovery and development of therapies for the treatment of haemophilia...
22 April 2016 | By Victoria White, Digital Content Producer
New data demonstrates daclizumab’s positive cognitive outcomes and safety profile in patients with relapsing-remitting multiple sclerosis (RRMS)...
18 April 2016 | By Victoria White, Digital Content Producer
Biogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients...
26 February 2016 | By Victoria White
Alprolix is a recombinant clotting factor therapy developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1...
18 January 2016 | By Victoria White
Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available there...
26 November 2015 | By Victoria White
Elocta will be the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days...
20 November 2015 | By Victoria White
Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel...
